The Benchmark Company has recently reduced NeoGenomics, Inc. (NEO) stock to Hold rating, as announced on January 13, 2025, according to Finviz. Earlier, on December 10, 2024, Jefferies had initiated the stock to Buy, setting a price target of $22. Craig Hallum also resumed Buy rating with a price target of $26. Additionally, BTIG Research reiterated Buy rating on December 29, 2023, with a target price of $21. Stephens analysts, in their report published on August 21, 2023, also raised rating and set a price target of $18 for NeoGenomics, Inc.’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
NeoGenomics, Inc. (NEO) Stock Trading Recap
On Monday, NeoGenomics, Inc. (NEO) stock saw a modest uptick, ending the day at $9.72 which represents a slight increase of $0.40 or 4.29% from the prior close of $9.32. The stock opened at $9.57 and touched a low of $9.37 during the day, reaching a high of $10.18. The volume of shares traded was 2.09 million exceeding the average volume of 1.46 million.
Sponsored
NEO Stock Performance and Moving Averages
In recent trading, NeoGenomics, Inc. (NEO) stock price has shown some volatility, fluctuating 10.08% over the last five trades and -1.07% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -28.21%, and it has plunged by -23.04% in the previous three months. Currently, NEO is trading at 3.50%, -9.20%, and -32.08% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, NEO, a Healthcare sector stock, is trading -49.15% below its 52-week high but remains 20.75% above its 52-week low. The Average True Range (ATR) (14 days) of 0.77 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
NeoGenomics, Inc.’s Profitability and Valuation Ratios
NeoGenomics, Inc.’s profitability metrics reveal financial health. The company currently boasts an operating margin of -12.72% and a profit margin of -11.92%, with a gross margin of -28.21%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, NeoGenomics, Inc.’s market capitalization stands at $1.25 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 28.10. Additionally, the Price-to-Sales Ratio is 1.89, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.38, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.20% of NeoGenomics, Inc. (NEO)’s shares, while financial institutions hold 101.20%.
